Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences

We recently published 10 Firms Shining Bright in a Bleeding Market. Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best-performing stocks on Monday.

Ocular Therapeutix rallied for a second day on Monday, adding 5.22 percent to finish at $11.89 apiece as investors repositioned portfolios ahead of two healthcare conferences in the next few days.

Last week, Ocular Therapeutix Inc. (NASDAQ:OCUL) said that its chairman, president, and CEO, Pravin Dugel, would participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, as well as the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025. Investors are expected to closely watch out for cues about the company’s pipeline developments and outlook.

Earlier this month, Ocular Therapeutix Inc. (NASDAQ:OCUL) widened its net loss by 90 percent to $69.4 million from $36.49 million in the same period last year.

Revenues also dropped by 5.8 percent to $14.5 million from $15.4 million year-on-year, due to a significantly more challenging reimbursement environment for its eye treatment, Dextenza, in 2025.

While we acknowledge the potential of OCUL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.